Suggested remit: To evaluate the benefits and costs of intrathechal idursulfase within its marketing authorisation for treating mucopolysaccharidosis type II for national commissioning by NHS England.
Following on from information provided to NICE by the company in July 2022, the appraisal of Intrathecal idursulfase for treating mucopolysaccharidosis type II [ID1223] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process HST
ID number 1223

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 July 2023 Discontinued. Following on from information provided to NICE by the company in July 2022, the appraisal of Intrathecal idursulfase for treating mucopolysaccharidosis type II [ID1223] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
13 July 2022 Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Highly Specialised Technology Evaluation of Intrathecal idursulfase for treating mucopolysaccharidosis type II. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
10 May 2018 - 08 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
14 May 2018 On receiving updated regulatory timing information from the company that markets the technology, NICE has agreed that holding a scoping workshop at this time would not be appropriate. Consequently the scoping workshop arranged for the 29 June 2018 will be cancelled and the consultation on the draft scope will not continue. The workshop and consultation will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause.

For further information on our processes and methods, please see our CHTE processes and methods manual